Introduction
The chicken retrovirus AEV (avian erythroblastosis virus) encodes two cooperating oncoproteins (v-ErbA and v-ErbB), which together cause rapid, lethal erythroleukemia in chicks. V-erbB encodes a truncated and mutated version of the avian epidermal growth factor receptor c-ErbB (Downward et al., 1984) . On its own, v-ErbB causes a mild leukemia with delayed onset (Kahn et al., 1986) and partially arrests erythroblast dierentiation (Beug et al., 1985; Fuerstenberg et al., 1990 Fuerstenberg et al., , 1992 .
V-ErbA is derived from c-ErbA, the avian thyroid hormone receptor (Sap et al., 1986; Weinberger et al., 1986) . V-ErbA cooperates with various oncoproteins derived from receptor tyrosine kinases and downstream signal transducers (Fms, Yes, Sea, Src, Fps, Ras and Raf) to induce enhanced proliferation plus a tight dierentiation arrest of erythroid cells Kahn et al., 1984 Kahn et al., , 1986 . In bone marrow erythroblasts cultivated in the presence of the c-ErbB ligand transforming growth factor (TGFa) or other, unidenti®ed growth factors, v-ErbA alone caused a similar dierentiation arrest (Casini and Graf, 1995; Gandrillon et al., 1989; Pain et al., 1991; Schroeder et al., 1990) .
The cellular counterpart of v-ErbA, c-ErbA/TRa, is a type II nuclear hormone receptor that forms a heterodimer with retinoic X receptor (RXR) and binds to DNA response elements irrespective of the presence of ligand (reviewed in Chambon, 1994; . In the absence of ligand, the TR/RXR complex represses arti®cial reporter genes harbouring a thyroid hormone response element (TRE) in their promoter. Repression is dependent on recruitment of corepressors (N-CoR or SMRT; Baniahmad et al., 1992; Chen and Evans, 1995; HoÈ rlein et al., 1995; Kurokawa et al., 1995) . Upon ligand addition, the corepressor is released and the reporter gene is activated through the C-terminal transactivation domain AF-2, most likely in cooperation with coactivators (CavailleÁ s et al., 1995; Kurokawa et al., 1995; Kamei et al., 1996; Lee et al., 1995; see also Figure 1a) . Surprisingly, cErbA/TRa can also transactivate reporters containing atypical TREs in the absence, but not in the presence of ligand (Bigler and Eisenman, 1994; Saatcioglu et al., 1993; Tomic-Canic et al., 1996) . The signi®cance of these potential mechanisms for the in vivo regulation of actual c-ErbA/TRa target genes remains to be determined.
V-ErbA is fused to viral Gag sequences at its N terminus and contains N-and C-terminal deletions as well as numerous point mutations (Munoz et al., 1988; Sap et al., 1986) . As a consequence, v-ErbA has lost the capacity to bind hormone and lacks the AF-2 transactivation domain that is well conserved between nuclear hormone receptors (Barettino et al., 1994; Danielian et al., 1992; Sap et al., 1986; Zenke et al., 1990) . V-ErbA retains the capacity to bind corepressors, which are essential for its function (see Figure 1a ; Chen and Evans, 1995; Damm and Evans, 1993) , and to repress arti®cial reporter genes via binding to certain TREs (Baniahmad et al., 1992; Chen and Evans, 1995; Sap et al., 1989) . V-ErbA also represses several genes induced by liganded c-ErbA/TRa, like carbonic anhydrase II, Band 3 and ALA-S, which are upregulated during terminal dierentiation . To some extent, V-ErbA counteracts the eects of ligand activated, endogenous c-ErbA, which accelerates erythroid dierentiation (Gandrillon et al., 1994; Schroeder et al., 1992a) . All these ®ndings have strengthened the proposal that v-ErbA functions as a dominant negative c-ErbA/TRa allele (Damm et al., 1989 ).
However, a number of recent observations are dicult to reconcile with this idea. Exogenous and endogenous c-ErbA/TRa and RARa can be dominant over v-ErbA, if activated by ligand (Disela et al., 1991; Schroeder et al., 1992a) . Furthermore, bona ®de dominant negative versions of c-ErbA and RARa require heterodimerization with RXR for function (Barettino et al., 1993; Durand et al., 1994; Selmi and Samuels, 1991) . V-ErbA lacks this ability due to a Pro to Ser mutation in the RXR heterodimerization domain (Au-Fliegner et al., 1993; Barettino et al., 1993) , while a v-ErbA lacking this mutation is able to heterodimerize with RXR (v-ErbA-r12; Barettino et al., 1993) . Finally, v-ErbA contains a mutation in the P-box of the DNA binding domain (DBD), implicated in DNA binding speci®city. This mutation is conserved in two v-ErbA proteins that evolved independently of each other (A Bauer and H Beug, unpublished) . It is required for transformation activity of AEV (Bonde et al., 1991) and results in an altered anity of v-ErbA for a number of arti®cial TREs (Smit-McBride and Privalsky, 1994) .
At present, de®nitive proof of the hypothesis that vErbA functions as a dominant-negative c-ErbA/TRa allele is dicult to obtain, mainly because target genes responsible for the v-ErbA induced dierentiation arrest are still unknown. Even in the known v-ErbA target genes (CAII, Band3, AlaS; Zenke et al., 1988) , DNA elements actually used by v-ErbA in vivo have not yet been identi®ed. Also, the multiple mutations in vErbA are likely to aect widely dierent functions in cErbA/TRa (Figure 1a ) rather than only counteracting a ligand activated TRa. Recently we showed that type I nuclear hormone receptors (estrogen receptor, ER; glucocorticoid receptor, GR) induce sustained proliferation in the absence of terminal dierentiation (referred to as`self renewal') in primary erythroid progenitors (Hayman et al., 1993; Schroeder et al., 1993; Steinlein et al., 1995; Wessely et al., 1997; von Lindern et al., submitted) . Both the GR and the ER required to cooperate with ligand-activated, endogenous receptor tyrosine kinases (c-ErbB, c-Kit) to induce self-renewal, showing little eect on their own. Likewise, c-ErbB and c-Kit failed to induce self renewal in the absence of active GR and ER; rather, they caused an increased proliferation (8 ± 10 instead of 4 ± 5 cell divisions) of the otherwise normally dierentiating erythroid progenitors (Wessely et al., 1997) .
In this paper we show that v-ErbA can substitute for the biological function of both the ER and the GR. VErbA mediated long term proliferation and arrested dierentiation in the presence of ER-and GR antagonists, strictly requiring cooperation with endogenous c-Kit. In contrast to normal progenitors, which require c-ErbB for sustained self renewal, c-Kit was completely sucient to induce self renewal in progenitors expressing v-ErbA. The v-ErbA-speci®c P-box mutation G61S was crucial for the differentiation arrest induced by v-ErbA, but much less important for cell proliferation in the presence of GR/ER antagonists. In contrast, both v-ErbA functions were impaired in a c/v-ErbA hybrid containing the entire c-ErbA DNA-binding domain. Finally, vErbA acted as a weak dominant-negative version of cErbA, while a v-ErbA variant restored in its ability to heterodimerize with RXR (v-ErbA r12) functioned as a truly dominant-negative c-ErbA/TRa allele. (a) Schematic representation of the domain structure of the thyroid hormone receptor c-ErbA/TRa, described to be important for the interaction of c-ErbA with DNA or with known proteins speci®cally binding to c-ErbA and modulating its function (i.e. the basal transcription machinery protein TFIIB, the transcription factor AP-1, the corepressors SMRT/NCoR, a growing family of coactivators and the heterodimerizing coreceptor RXR). A similar map is shown for v-ErbA, the oncogenic version of TRa. The virus derived Gag sequence, the N-terminal and C-terminal deletions and the locations of the thirteen point mutations in v-ErbA (solid dots) are indicated. Due to these mutations, v-ErbA no longer binds T3, has lost the ability to interact with some of its partners (indicated by empty rather than ®lled domains) and exhibits an altered/relaxed DNA binding speci®city. (b) Location of the mutations in the various v-ErbA variants used in this paper. Solid dots represent amino acids still in v-ErbA con®guration, open dots indicate backmutation to the respective aminoacid of cErbA. In v-ErbA-S61A, the grey dot stands for a serine to alanine exchange in the P-box, corresponding to the respective aminoacid in the estrogen receptor
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Results

V-ErbA supports outgrowth of chicken bone marrow cells in the absence of steroids
In a ®rst series of experiments, we investigated whether v-ErbA can substitute for the requirement for the ER and/or GR ligands estradiol and dexamethasone in erythroid progenitor self renewal (Wessely et al., 1997) .
Freshly prepared chicken bone marrow cells were infected with a retroviral vector expressing the v-ErbA oncoprotein, and the infected cells were cultivated in the presence of SCF plus TGFa Figure 2a ). First, we compared the growth behaviour of v-erbA infected bone marrow cells with that of control cells containing empty vector. As expected, control cultures proliferated in the presence of both steroid agonists, but not with the respective steroid antagonists ( Figure  2b , left panel; Wessely et al., 1997) . In contrast, vErbA expressing erythroblasts ( Figure 2a ) were able to undergo sustained self renewal in the presence of either steroid agonists or antagonists, regardless of their combination ( Figure 2b , right panel). The growth rate of the v-ErbA expressing cells was similar under all conditions, although cells grew slightly better in the presence of E2 than in ICI. In addition, Dex seemed to slightly inhibit cell growth as compared with its antagonist (ZK). These results show that v-ErbA can abrogate the requirement for activated GR and ER in the induction of erythroid progenitor self renewal.
A functional c-ErbB is not required for long-term self renewal of v-erbA-expressing progenitors As shown earlier, an active GR as well as upregulation of c-ErbB is required for the development of self renewing SCF/TGFa progenitors (Hayman et al., 1993; Steinlein et al., 1995; Wessely et al., 1996) . Since vErbA cooperates with v-ErbB in AEV-induced leukemia, we expected that cells expressing v-ErbA would also require c-ErbB upregulation for long term self renewal. Accordingly, v-ErbA-expressing bone marrow cells were grown in the presence of SCF, TGFa, ICI and ZK for 20 days. They were then withdrawn from growth factors, restimulated with SCF, TGFa or no factor and tested for expression of bioactive c-Kit and c-ErbB on a phosphotyrosine Western blot. Control SCF/TGFa progenitors grown in the presence of SCF, TGFa, E2 and Dex for 20 days were analysed similarly.
As expected, the control cells expressed both c-Kit and c-ErbB. Surprisingly, however, the v-ErbA cells completely lacked c-ErbB expression (Figure 3a) . These data were con®rmed by reprobing the blots with anti-cKit and anti-c-ErbB antibodies (data not shown). Thus, erythroid progenitors infected with v-ErbA are able to undergo long-term self renewal in cooperation with c-Kit only.
To further substantiate this ®nding, we made use of a speci®c inhibitor of the mammalian EGF receptor tyrosine kinase (PD153,035; Fry et al., 1994) . This inhibitor completely blocks ligand-induced autophosphorylation of avian c-ErbB, autophosphorylation of c-ErbB substrates and the induction of self renewal by c-ErbB, but fails to aect c-Kit, the EpoR or the Insulin ± and IGF-1 receptors (Mellitzer et al., 1996; G Mellitzer and H Beug, unpublished) . When v-ErbA expressing erythroblasts were grown in media containing SCF (minus or plus TGFa) together with ICI, and ZK plus a fully inhibiting dose of PD153,035 (see Materials and methods), cultures containing PD153,035 showed the same long-term proliferation (25 days) as control cultures without PD153,035 ( Figure 3b ). As expected, PD153,035 also inhibited proliferation of c-ErbB-expressing control cells lacking v-ErbA (grown in SCF, TGFa, Estradiol and Dexamethasone; Hayman et al., 1993) .
Taken together these results indicate, that v-ErbA not only substitutes for the GR and ER in stimulating the outgrowth of normal progenitors but also abrogates the strict requirement of normal progenitors for an activated c-ErbB to induce long-term self renewal.
V-ErbA requires cooperation with c-Kit to induce proliferation and arrest erythroid dierentiation
Having shown that cooperation of c-Kit with v-ErbA is sucient for sustained erythroblast proliferation, we next asked whether c-Kit was also sucient to trigger a v-ErbA induced dierentiation arrest. Alternatively, this might require ErbB as in AEV-induced erythroleukemia or v-ErbA could arrest erythroid dierentiation and stimulate proliferation on its own (Gandrillon et al., 1989; Pain et al., 1991) . VErbA-expressing erythroblasts grown in SCF plus ICI and ZK were induced to dierentiate by addition of chicken erythropoietin (Epo) and insulin, in the presence or absence of SCF (see Materials and methods). Control cells infected with empty vector were treated similarly. In addition to morphological characteristics, three quantitative dierentiation parameters were monitored; proliferation, hemoglobin accumulation and reduction of cell size (Beug et al., 1994; Dolznig et al., 1995; Kowenz et al., 1987) .
In the absence of SCF, control erythroblasts lacking v-ErbA matured into erythrocytes within 3 to 4 days, as indicated by their oval shape, condensed nucleus and intense staining for hemoglobin ( Figure 4a ). In addition the cells were fully arrested in proliferation (Figure 4b ), accumulated high hemoglobin levels ( Figure 4c ) and reduced their size from 4250 femtoliters (¯) to 5100( Figure 4d ). Addition of SCF delayed, but not inhibited this terminal dierentiation program induced by Epo/ insulin. Cells required 6 ± 7 days instead of 4 ± 5 days to mature into erythrocytes ( Figure 4a ) and showed the corresponding delays in proliferation arrest, hemoglobin accumulation and size decrease ( 
A region in the v-ErbA P-box is crucial for v-ErbA function
If a major function of v-ErbA is to abrogate the requirement for active steroid hormone receptors in erythroid progenitor self renewal, v-ErbA target genes may represent ER/GR target genes, instead of or in addition to c-ErbA/TRa target genes. In line with this, v-ErbA carries a mutation in the P-box of the DBD (implicated in speci®c DNA binding). A v-ErbA protein carrying a backmutation to the c-ErbA con®guration at position 61 (S61G) failed to bind to TRE-pal and was unable to transform erythroblasts together with v-ErbB (Bonde et al., 1991) . A second, arti®cial mutation at the same position (S61A, resembling the ER at this position) neither aected TRE-pal binding nor transforming activity of v-ErbA.
First we checked the eect of P-box mutations in vErbA on the proliferation of normal erythroid progenitors. V-ErbA proteins harboring the S61G-or the S61A mutations ( Figure 1b) were expressed in normal erythroblasts and tested for their ability to induce sustained proliferation in the presence of SCF plus ICI and ZK. As expected (Bonde et al., 1991) , the v-ErbA-S61A protein led to a similar or even faster proliferation than v-ErbA wt in erythroblasts exposed to SCF plus steroid antagonists ( Figure 5 ). Surprisingly, however, the v-ErbA-S61G protein also sustained proliferation in the presence of SCF plus steroid antagonists, despite its inability to transform in the earlier experiments (Bonde et al., 1991) .
Next, we analysed the dierent v-ErbA proteins for their ability to arrest erythroblast dierentiation. Cells expressing v-ErbA-S61G and v-ErbA-S61A were seeded in Epo/insulin-containing dierentiation medium in the presence or absence of SCF and analysed for dierentiation parameters as above. Cells expressing v-ErbA-wt or infected with empty vector were treated similarly as positive and negative controls, respectively. In line with its transforming ability, v- Figure 2 were grown in CFU-E medium containing SCF, ICI and ZK, further supplemented with TGFa (5 ng/ml) or a speci®c inhibitor of the c-ErbB receptor tyrosine kinase (PD 153,035) at a dose previously determined to completely inhibit the TGFa-induced growth of SCF/TGFa progenitors (5 mM). Cells were counted and cumulative cell numbers determined as in Figure 2 ErbA-S61A showed a phenotype similar to v-ErbA wt ( Figure 6 ). In the presence of SCF, the erythroblasts were completely arrested in differentiation. Surprisingly, in the absence of SCF, the S61A protein still caused a partial dierentiation arrest, while v-ErbA-wt erythroblasts dierentiated completely under these conditions. Thus v-ErbA-S61A represents a superactive version of v-ErbA, as was particularly evident with respect to cell morphology and hemoglobin accumulation (Figure 6a , b, triangles).
The v-ErbA-S61G protein, on the other hand, was clearly defective in its ability to inhibit dierentiation. In the presence of SCF, S61G cells formed a mixed population of immature, partially mature and mature cells (Figure 6a ), reduced their size to &100¯and accumulated clearly elevated levels of hemoglobin (Figure 6b, c; circles) . These data indicated that vErbA-S61G is still able to substitute for the proliferation induction caused by ligand-activated ER plus GR, but is severely aected in its ability to induce a dierentiation arrest. In contrast, v-ErbA-S61A is hyperactive in arresting dierentiation of normal erythroid progenitors.
Gene expression analysis in cells expressing v-ErbA Pbox mutations identify c-myb as a potential v-ErbA target gene
The above data show, that the domain of v-ErbA surrounding serine 61 must be of crucial importance for the ability of v-ErbA to arrest dierentiation. Therefore, we compared v-ErbA-wt and the two P-box mutations for their upregulation of potential target genes, using Northern blot analysis. Genes analysed included known v-ErbA target genes like CAII, band 3 or ALA-S . We also analysed cmyb, which is speci®cally expressed in immature erythroid cells (Dolznig et al., 1995) and was recently identi®ed as a potential target gene of the GR, its mRNA being upregulated after ligand stimulation (Wessely et al., 1997) .
As shown above, v-ErbA was dependent on a SCFactivated c-Kit to arrest dierentiation, while it had no eects in its absence. Erythroblasts expressing v-ErbAwt, v-ErbA-S61A, v-ErbA-S61G or no ErbA were therefore induced to dierentiate in Epo/insulin plus or minus SCF, for 2, 4 or 6 days. Cell lysates were then processed for Northern analysis. Primary erythroblasts infected with v-erbA and grown for 10 days in SCF, ICI and ZK were induced to dierentiate with anemic serum plus insulin as described, in the absence (Epo/Ins; open squares) or presence (SCF+Epo/Ins; closed squares) of aSCF (panels v-ErbA'). As control cells, 3 day-old cultures of puri®ed SCF progenitors (Dolznig et al., 1995) were treated similarly (panels Control'). (a) Aliquots of the dierentiating cells were cytocentrifuged onto slides after 4 (Epo/Ins) or 6 days (SCF+Epo/Ins), stained with neutral benzidine plus histological dyes and images were recorded using a blue ®lter to reveal staining for hemoglobin (see Materials and methods). (b ± d) At the times indicated, aliquots of the cultures were analysed for hemoglobin content (c, rel. units, normalized to cell volume) cell volume (d, expressed in femtoliters;¯) and cumulative cell numbers (b), as described in Materials and methods Although CAII, band 3 and AlaS were identi®ed as v-ErbA target genes , these genes were strongly upregulated in v-ErbA-wt expressing erythroblasts grown in Epo/insulin without SCF (Figure 7a , left panels and data not shown). Simultaneously, c-myb expression was completely repressed 3 ± 4 days after dierentiation induction. In contrast, upregulation of CAII, band 3 and Ala-S was strongly suppressed in the presence of SCF, while high levels of c-myb expression were maintained. Thus cooperation between v-ErbA and activated c-Kit is also required to suppress the expression of v-ErbA target genes.
The S61A v-ErbA mutant resembled v-ErbA wt with respect to erythrocyte gene repression and maintenance of c-myb mRNA levels in presence of SCF. Surprisingly, upregulation of band 3 and ALA-S mRNA was at least partially repressed even in the absence of SCF (data not shown), in line with the partially differentiation arrested phenotype displayed by the cells under these conditions (Figure 6b) . Surprisingly, the S61G vErbA mutant was unable to repress upregulation of CAII, band 3 and ALA-S mRNA upon dierentiation induction in the presence of SCF (Figure 7b , right panels). This corresponded to the leaky dierentiation arrest seen under these conditions (Figure 6b) . Interestingly, however, v-ErbA-S61G was able to maintain high levels of c-myb mRNA expression, despite its inability to arrest dierentiation. This ®nding may explain, why v-ErbA-S61G retained its ability to induce proliferation in the absence of steroids.
In summary, the results obtained so far show that v-ErbA function is speci®cally aected by P-box mutations known to alter DNA binding speci®city. This applies for interference with Epo/SCF-induced dierentiation and regulation of target gene expression, but not for proliferation induction in the complete absence of steroids. A mutation back to the c-ErbA/TRa con®guration strongly reduces vErbA activity in this respect, while a mutation to a con®guration typical of the ER even enhances v-ErbA activity.
A v-ErbA/c-ErbA chimera containing the entire c-Erb-DNA binding domain fails to arrest dierentiation
The above results indicated that the alterations in DNA-binding speci®city induced by mutations in the respective domains of v-ErbA were crucial for dierentiation arrest. This prompted us to analyse, if a v-ErbA protein carrying the entire DBD of c-ErbA would show aspects of v-ErbA activity. The latter result would be the expected one, if v-ErbA would function as a dominant-negative version of TRa/cErbA. If, on the other hand, v-ErbA would recognize other DNA binding elements than TRa/c-ErbA, such a construct should either be biologically inactive or display some, but not all characteristics of overexpressed c-ErbA .
To study this, a v-ErbA/c-ErbA hybrid was constructed in which the six point mutations of vErbA adjacent to the gag fusion were reverted to the cErbA con®guration (v-erbA-cl-6; see Figure 1b ). This mutant corresponded to c-ErbA in the two Zn-®ngers of the DBD, in the two mutations N-terminal of the DBD recently demonstrated to contribute to DNA binding speci®city and in the two mutations in the hinge region C-terminal of the DBD. To rule out, that v-ErbA activity was altered by the cErbA con®guration in this`hinge' region, a construct containing these two mutations only on a v-ErbA background (v-ErbA-c56, Figure 1b ) was used as a control. Retroviruses expressing these two constructs were then used to infect normal erythroid progenitors. Unexpectedly, the v-ErbA-cl-6 infected cells failed to grow in the media used above. We therefore grew the infected cells in SCF, ICI, ZK plus IGF-1, a factor combination allowing the expansion of erythroblasts expressing other mutant ErbA proteins unable to stimulate growth in standard media (A Bauer, unpublished). After expansion, cells expressed the expected v-ErbA proteins at high level (data not shown). Cells were then induced to dierentiate in medium containing Epo/Insulin in the presence or absence of SCF. In the absence of SCF, both cell types showed the expected terminal dierentiation within 4 days (data not shown). In the presence of SCF, the vErbA-c56 protein harboring a v-ErbA DBD caused the expected, complete dierentiation arrest (Figure 8a ± c,  squares) . In contrast, the v-ErbA-cl-6 hybrid was completely unable to arrest dierentiation, giving rise to a similar phenotype as the cells infected with empty vector (Figure 8a ± c and data not shown) . Thus, a vErbA protein with the DNA binding speci®city of c- Figure 5 V-ErbA proteins carrying P-box mutations induce proliferation in the absence of steroids. Bone marrow cells were infected with virus encoding v-erbA-S61A (squares), v-erbA-wt (circles) and v-ErbA-S61G (triangles), respectively. The respective erythroid progenitors were grown in SCF, ZK plus ICI. Cultures were counted at the times indicated (days after infection) and cumulative cell numbers determined as described in the legend to Figure 2 
Mechanism of v-ErbA action
ErbA is severely impaired in its function in erythroblasts.
Restoration of RXR heterodimerization to v-ErbA increases its activity and renders it dominant over ligandactivated TR and RAR
Our demonstration that v-ErbA acts by substituting for the biological function of two endogenous steroid hormone receptors, ER and GR, challenges the established model of v-ErbA action, i.e. that it acts as a dominant negative TR (Damm et al., 1989; Sap et al., 1989) . Recently, bona ®de dominant negative retinoic acid receptors were described. These required an intact RXR heterodimerization domain for full activity (Barettino et al., 1994; Durand et al., 1994) . VErbA, on the other hand, is unable to heterodimerize with RXR due to a point mutation in the heterodimerization domain (Barettino et al., 1993; Selmi and Samuels, 1991) . Therefore, it was of interest to compare v-ErbA-wt to a v-ErbA mutant (v-ErbA-r12; Damm et al., 1987) that has regained the ability to heterodimerize with RXR (Figure 1b ; Barettino et al., 1993) . When v-ErbA-r12 was expressed in SCF progenitors and compared to wild-type v-ErbA, it supported the sustained self renewal of erythroid progenitors in the presence of SCF plus ICI and/or ZK, even causing a clearly accelerated proliferation in comparison to v-ErbA-wt. In addition, v-ErbA-r12 even partially arrested dierentiation in the absence of SCF (data not shown) con®rming its action as a superactive version of v-ErbA (Damm et al., 1987) .
Next, we analysed, if the gain of RXR heterodimerization ability in v-ErbA-r12 would alter its ability to act as a dominant-negative version of c-ErbA/TRa. Ligand activation of c-ErbA/TRa-RXR heterodimers by their ligands, T3 plus 9-cis RA, is known to inhibit proliferation and induce dierentiation in normal erythroid progenitors (Gandrillon et al., 1994; Schroeder et al., 1992a,b) . However, v-ErbA-wt was quite inecient in suppressing these eects of endogenous cErbA/TRa-RXR (Disela et al., 1991; Schroeder et al., 1992a) .
Primary erythroid progenitors expressing wt-v-ErbA or v-ErbA-r12 were cultivated in the presence of SCF, Epo and insulin. Thyroid hormone (T3) plus 9-cis retinoic acid (9cRA) were added to aliquots of these cultures. In the absence of T3/9-cis RA, both v-ErbA- 
Discussion
In this paper, we have addressed two aspects of v-ErbA function as a leukemia-inducing oncoprotein: possible mechanisms of action and cooperation with endogenous receptor tyrosine kinases. In both cases, the use of primary, normal erythroid progenitors as an improved in vitro cell system allowed us to come up with novel, unexpected answers. Firstly, we challenge the view that the action of v-ErbA as a dominant-negative TRa/cErbA is the sole or predominant mechanism by which v-ErbA contributes to leukemogenesis (Damm et al., 1989; Sap et al., 1989) . Rather, we provide evidence that v-ErbA functionally replaces the action of steroid hormone receptors (ER and GR) which turned out to be key regulators of erythroid progenitor proliferation and dierentiation (Wessely et al., 1997; von Lindern et al., submitted) . Secondly, we show that v-ErbA requires the cooperation with speci®c, endogenous receptor tyrosine kinases while earlier work suggested that v-ErbA could transform on its own (Casini and Graf, 1995; Gandrillon et al., 1989; Pain et al., 1991) . The speci®city of this cooperation is shown by the fact, that c-Kit but not the receptors for IGF-I or insulin can activate v-ErbA function.
Cooperation of v-ErbA with activated receptor tyrosine kinases
The observation that v-ErbA was completely inactive in normal erythroid progenitors and required the presence of an active receptor tyrosine kinase in order to stimulate proliferation and arrest dierentiation was unexpected. Earlier work had suggested that v-ErbA could function on its own (Gandrillon et al., 1989; Pain et al., 1991) , or at least be partially active by arresting dierentiation (Schroeder et al., 1990) . However, some of these studies employed temperature-sensitive tyrosine kinase oncoproteins which may display residual activity at the nonpermissive temperature (Schroeder et al., 1990; Zenke et al., 1988) . Alternatively, complex media were used (Gandrillon et al., 1989; Pain et al., 1991) , containing ligands for c-ErbB and/or endogenous, unknown receptor tyrosine kinases (G Mellitzer and HB, unpublished) . Therefore, v-ErbA was most likely activated in these studies by the oncogenic or endogenous tyrosine kinases still active in the cells. All erythroid progenitors express relatively high levels of c-Kit. Thus, endogenous c-Kit is a likely candidate to substitute for tyrosine kinase oncoproteins (v-ErbB, v-Sea) shown to cooperate with v-ErbA in earlier studies Knight et al., 1988) . The ®nding that a novel type of retrovirus expressing very high v-ErbA levels was able to cause leukemia in the absence of an exogenous tyrosine kinase (Casini and Graf, 1995) is most likely also explained by cooperation of v-ErbA with c-Kit, since cKit expressing proerythroblasts bind to stromal cells during erythropoiesis in vivo which express a membrane-bound version of the c-Kit ligand (Nibbs et al., 1993) . Hybridizations were performed sequentially with 32 P-labelled cDNA probes for genes upregulated during terminal differentiation (band 3, Ala-S, CA-II) as well as for the erythroblast-speci®c c-myb RNA, known to be rapidly downregulated upon dierentiation induction (Dolznig et al., 1995) . Hybridization with a probe to 18 S ribosomal RNA (18S rRNA) is shown as a control for equal loading Immature erythroid cells also express and respond to the IGF-I receptor, while more mature cells require an active insulin receptor for terminal dierentiation (MvL, unpublished results). In contrast to its ecient cooperation with c-Kit, v-ErbA is totally inactive in the presence of the latter, ligand-activated receptor tyrosine kinases. This was an unexpected ®nding in the light of earlier studies showing cooperation of v-ErbA with a variety of receptor tyrosine kinase-and signaltransducer oncoproteins (see Kahn et al., 1986 , and references therein). It also suggests that speci®c signal transduction pathways are involved in the cooperation of v-ErbA with receptor tyrosine kinases.
The mechanism of v-ErbA and c-Kit cooperation is probably indirect. Signal transduction events initiated by c-Kit could activate transcription factors acting together with v-ErbA on common target genes (Hayman and Beug, 1992) . Alternatively, c-Kit activated transcription factors could act on a complementary set of target genes cooperating with v-ErbA target genes. Recent results on the cooperation between the GR and endogenous c-Kit in primary erythroid progenitors (Wessely et al., 1997) are in accord with such mechanisms. Ligand activated c-Kit fails to cooperate with the GR in GRE containing reporter plasmid or in upregulation of c-myb mRNA. In
Control (no ErbA) a b c Figure 8 The DNA binding domain of c-ErbA is unable to cause dierentiation arrest and maintain proliferation of erythroid cells. 10 day-old erythroblasts expressing the v/c-ErbA chimera v-ErbA-cl-6 (containing the entire DBD of c-ErbA) were grown and selected in CFU-E medium supplemented with SCF, IGF-1, ICI and ZK. Positive (v-ErbA-c56) and negative control erythroblasts (no v-ErbA) were grown similarly. The erythroblasts obtained were then induced to dierentiate in media containing anemic serum (Epo), Insulin and SCF. Cytospin preparations of cell aliquots removed at day 6 were processed for benzidine staining and image processing under blue light (a) as described in the legend to Figure 4 . At the times indicated, cumulative cell numbers (b) and hemoglobin content (c; normalized to cell volume) was determined as in Figure 4 contrast, SCF-activated c-Kit caused upregulation of cjun mRNA independent of the GR. v-ErbA resembles the GR in its failure to delay dierentiation in the absence of SCF, in its requirement for cooperation with ligand activated c-Kit and in its inability to cooperate with insulin-or IGF-1 receptors. Thus, c-Kit and either GR or v-ErbA may regulate separate sets of target genes, which only together can induce proliferation and arrest dierentiation in erythroblasts.
On the other hand, phosphorylation of v-ErbA as a consequence of c-Kit activated signal transduction may also play a role. In cooperation with the oncoproteins v-ErbB and v-Sea, a v-ErbA mutant with two serines (S16/17) changed to alanines was biologically inactive. V-ErbA wt was similarly inactivated by the serine kinase inhibitor H7, at concentrations which prevented in vivo phosphorylation of v-ErbA at these residues and were nontoxic in cells lacking v-ErbA (Glineur et al., 1990) . It remains to be determined, however, if v-ErbA phosphorylation at these residues is important in normal erythroid progenitors and in the cooperation of v-ErbA with endogenous c-Kit.
DNA binding by v-ErbA
Central to this paper was the observation, that v-ErbA could abrogate the requirement for two ligandactivated steroid hormone receptors, ER and GR, in regulation of erythroid progenitor proliferation and dierentiation. Unfortunately, an obvious, straightforward explanation of these results is lacking due to our ignorance of relevant c/v-ErbA and steroid hormone receptor target genes. However, our ®ndings could be explained in several ways, if one allows for some still highly speculative assumptions. For instance, v-ErbA could regulate GR and/or ER target genes by binding to (perhaps unusual) EREs and GREs. Alternatively, c-ErbA/TRa (and therefore also v-ErbA) could act downstream of the GR and ER. According to this idea, ligand activation of the ER and/or GR could upregulate c-ErbA/TRa and/or stabilize it in a nonliganded conformation, causing c-ErbA/TRa to function like v-ErbA.
Altered DNA-binding speci®city? If v-ErbA would substitute for ER/GR function by binding to ER/GR target genes, this would require its ability to bind to respective promoters containing EREs or GREs. Nuclear hormone receptor response elements consist of`half sites', i.e. consensus sequences that are oriented as repeats in various orientations. Most superfamily members, including the ER and TR-a/c-ErbA, bind a half site with the ERE consensus AGGTCA, while the GR (and the GR related progesterone-androgen-and mineralocorticoid-receptors) binds a half site of the Figure 9 Restoration of RXR heterodimerization in v-ErbA renders infected erythroblasts unresponsive to dierentiation induction by T3 plus 9cRA. Erythroid progenitors infected with v-ErbA-wt (panels`wt-ErbA') or v-ErbA-r12 (ErbA-variant able to heterodimerize with RXR; panels`r12-ErbA') were induced to dierentiate in aSCF, Epo and Insulin, in the presence (T3 plus 9-cis RA; closed squares) or absence (Control; open squares) of the TRa-ligand trijodothyronine (T3) and the RXR ligand 9-cis-retinoid acid (9-cis RA). Cells were analysed for morphology and hemoglobin staining after 6 days (a) as described in the legend to GRE consensus AGAACA (reviewed by Zilliacus et al., 1995) . Since nuclear hormone receptors generally bind as dimers, it is the orientation and spacing of the half sites plus the¯anking sequences that determines which receptor complex can bind (Mader et al., 1993) . For instance, the ER will bind a palindromic element with a three nucleotides spacer, while a c-ErbA/RXR heterodimer will bind the same half sites in a palindromic orientation without spacing (TREpal) or as a direct repeat spaced by four nucleotides (DR4). The avian TRb receptor also binds as a homodimer (SjoÈ berg and VennstroÈ m, 1995) to everted repeat elements like the F2 element (Baniahmad et al., 1990 (Baniahmad et al., , 1992 . The available evidence suggests, that the DNA binding speci®city of v-ErbA is indeed altered and/or relaxed in comparison to c-ErbA. Firstly, mutations activating c-ErbA as an oncogene, such as the G to S exchange in the P-box, may facilitate binding of v-ErbA to half sites dierent from the ERE consensus Schwabe et al., 1993; Smit-McBride and Privalsky, 1994; Wahlstrom et al., 1996) . Since speci®c DNA binding is not only achieved by positive selection of the`®tting' half site, but also by selection against half sites (Mader et al., 1989; Truss et al., 1991; Zilliacus et al., 1992) , v-ErbA may even bind to half sites normally recognized by the GR, analogous to a GR mutant carrying a Ser to Ala P-box mutation (GR-S459-A). This mutant still binds to bona ®de GREs, but recognizes other, non-GRE elements as well (Lefstin et al., 1994) .
Secondly, v-ErbA does no longer heterodimerize with RXR. As a result, it has a strongly enhanced anity to certain DNA elements (the everted repeat element F2) to which it seems to bind as a homodimer, like the TRb (WahlstroÈ m et al., 1992) . This may enable v-ErbA to bind to ERE/TRE or even GRE half sites in (an) orientation(s) dierent from that used by c-ErbA/ TR-a/RXR heterodimers.
Does c-/v-ErbA act downstream of ER/GR?
The obvious diculties in explaining the action of v-ErbA by assuming it to bind to ERE or GRE-containing target genes could be completely avoided by the hypothesis, that nonliganded c-ErbA/TRa acts downstream from the ER and GR and is responsible for the E2/Dex-induced proliferation and dierentiation arrest in erythroblasts. The function of the ER and GR in regulating erythroid dierentiation would then be to upregulate c-ErbA/TR-a expression and/or to stabilize c-ErbA/TR-a in a non-liganded, proliferation-stimulating conformation, for instance by inducing the expression of respective, unknown c-ErbA/TR-a binding proteins. According to this idea, v-ErbA would act as an ErbA protein constitutively`frozen' in this nonliganded conformation and the function of the various v-ErbA mutations would be to stabilize this conformation.
An experimentally testable prediction from this idea would be, that an overexpressed c-ErbA/TR-a should function exactly like v-ErbA, if completely withdrawn from all ligands (i.e. T3 and retinoids). Unfortunately, evidence for this notion is at best circumstantial, given the fact that no good thyroid hormone antagonists exist to date. Firstly, Gandrillon et al. (1994) demonstrate, that normal erythroid progenitors fail to dierentiate, if totally deprived from T3 and retinoids by a combination of serum stripping and treatment with an anti RA antibody. And secondly, overexpressed gag-c-ErbA exhibited a partial differentiation arresting ability if tested in erythroblasts under conditions where T3 and/or retinoids had been partially removed . We have initiated experiments expressing gag-fused c-erbA in primary erythroblasts to clarify this question.
Does v-ErbA function via transactivation, transrepression or both?
TRa/c-ErbA is always localized in the nucleus and represses transcription in the absence of ligand. Repression is mediated through the`hinge' region, which binds two recently described corepressors in the absence of ligand (Chen and Evans, 1995; HoÈ rlein et al., 1995; Kurokawa et al., 1995) . Addition of ligands releases the corepressors and turns c-ErbA into a transactivator, involving the AF-2. This domain is highly conserved throughout the nuclear hormone receptor superfamily (Barettino et al., 1994; Durand et al., 1994; Fawell et al., 1990 ) but deleted in v-ErbA . V-ErbA retained the ability to bind corepressors and acts as a constitutive repressor of transient transcription of reporter genes, regardless of the presence or absence of T3. Interestingly, a biologically inactive, mutant v-ErbA (td 359; Damm et al., 1987) was unable to bind corepressor due to an aminoacid exchange in the hinge region and a c-ErbA carrying this mutation was defective for repression in absence of thyroid hormone (Chen and Evans, 1995; Damm and Evans, 1993) . All these data argue, that constitutive repression of a set of target genes is the main function of v-ErbA. However, v-ErbA acts as a ligand-dependent transactivator in yeast (Sande and Privalsky, 1994) and as a ligand-independent transactivator (actually repressed by ligand) on unconventional TREs (RSV-LTR, clone 112; Bigler and Eisenman, 1994; Saatcioglu et al., 1993) or keratin promoters (Tomic-Canic et al., 1996) . Interestingly, transactivation of RSV-LTR-driven reporters required the Nterminal AF-1 domain of v-ErbA and this function was constitutively active in v-ErbA (Saatcioglu et al., 1993) . In TRb, the AF-1 domain has also been implicated in transactivation by TRb-homodimers binding to everted repeat TREs (SjoÈ berg and VennstroÈ m, 1995). Finally, v-ErbA required interaction with unknown nuclear factors to transactivate via a TRE in the rat GH promoter. This suggests that the promoter context can be crucial to convert v-ErbA into a transactivator (Nagl et al., 1995) . Our ®nding, that v-ErbA maintains high c-myb expression even in v-ErbA-S61G-expressing erythroblasts, which can undergo partial dierentiation and exhibit no repression of the v-erbA target genes CAII, Band 3 and Ala-S, would be in line with the idea that v-ErbA and nonliganded c-ErbA can also function by gene transactivation. This may involve the Nterminal`AF-1 domain' after phosphorylation of Ser 16/17 (Glineur et al., 1990) .
Conclusions
In this paper we presented the surprising ®nding that a mutant type II nuclear hormone receptor (v-ErbA) can substitute for the function of two class I steroid hormone receptors (ER and GR). The altered DNA binding speci®city and hetero/homodimer formation of v-ErbA would not contradict the assumption that v-ErbA could function by regulating ER/GR target genes by binding to EREs and GREs in the respective promoters. On the other hand, an alternative model of ErbA function postulates (i) that c-ErbA not only induces proliferation and induces dierentiation in the presence of ligands, but also induces proliferation and arrests dierentiation when stabilized in a nonliganded conformation by GR/ ER and (ii) that v-ErbA acts as a constitutively active, nonliganded c-ErbA. While this idea is compatible with essentially all published data on c-and v-ErbA function, at present it lacks any substantial experimental support. Further work will concentrate on resolving, if any of these quite speculative models about ErbA function can be con®rmed by experimental data.
Materials and methods
Viruses and cells
The construction of the retroviral vectors pCRA (v-erbAwt-neo) and pCRr12 (v-erbA-r12-neo) has been described earlier (Damm et al., 1987; Jansson et al., 1987) . The retroviral vectors expressing v-erbA-S61G or v-erbA-S61A (Bonde et al., 1991) were constructed by exchanging a BamHI/EcoRV fragment of pCRA with the respective BamHI/EcoRV fragments of v-erbA-S61G or v-erbA-S61A (a kind gift of M Privalsky, Davis, CA, USA).
The c/v-ErbA chimeras c1 ± 6 and c56 were expressed from derivatives of the retrovirus vector CV-v-erbA-Neo, remodelled from SFCV-LE (Fuerstenberg et al., 1990) . SFCV-LE was digested with XhoI and BglII, circularized, digested again in the HindIII and EcoRI sites of the polylinker region, blunted and ligated with a Neomycin selection marker cassette. The resulting intermediate was then used for insertion of gag-v-erbA (derived from pCRA) into BamHI/ BsmI sites of this vector in a two-step cloning procedure. The resulting CV-v-erbA-Neo retrovirus vector contains the gag-verbB gene and the neomycin gene, both driven by the 5' LTR promoter. The v-erbA c1 ± 6 and verbA c56 constructs were generated by exchanging the BamHI/EcoRV fragment of gagv-ErbA wt in CV-v-erbA-Neo with the respective fragments from the retroviral constructs V3 and V2 (Munoz et al., 1988) .
Chicken embryo ®broblasts expressing the above retroviral constructs were generated by cotransfection with RCAN helper virus DNA as described earlier (Frykberg et al., 1983) and G418 selection. The infected ®broblasts were expanded in standard growth medium (Graf, 1973) . SCF progenitors and SCF/TGFa progenitors were grown from the bone marrow of 3 ± 10 day old Spafas chicks as described previously (Hayman et al., 1993; Steinlein et al., 1995) .
Infection of primary erythroblasts with retroviruses
To infect primary erythroblasts, freshly prepared chicken bone marrow cells or 10 day old SCF/TGFa progenitors were cocultivated with mitomycin-C-treated CEF expressing the respective retroviral constructs for 2 days (Fuerstenberg et al., 1992) . During infection, the cells were grown in modi®ed CFU-E medium supplemented with aSCF (100 ng/ml) and the steroids estradiol and dexamethasone (5610 77 M).
Proliferation kinetics
The cells were then further propagated as a mass culture in modi®ed CFU-E medium (Beug et al., 1985) , containing combinations of the following factors (as indicated in the text): aSCF (100 ng/ml; Beug et al., 1995) , TGFa (2 ng/ml, Promega), PD153,035 (5 nM), the steroids estradiol (1 mM) and dexamethasone (1 mM), or the steroid antagonists ICI 182780 (5610 77 M; Schroeder et al., 1993) and ZK 112,993 (1.5610 76 M, a kind gift of Dr E MuÈ llner, Vienna Biocenter, Vienna, Austria). To follow the growth kinetics of the erythroblast cultures, cells were subjected to daily partial medium changes plus re-addition of fresh factors. They were kept at densities between 2 and 4610 6 /ml by appropriate dilution and aliquots counted in an electronic cell counter (CASY-1, SchaÈ rfe-System, FRD). Cumulative cell numbers were determined as described (Fuerstenberg et al., 1992) .
Dierentiation kinetics
Cells were washed twice in serum-free medium and seeded at 2610 6 cells/ml into 35 mm dishes containing 2 ml of dierentiation medium , supplemented with anemic serum (3% of pretested, high titer batches, as a source for avian erythropoietin; Kowenz et al., 1987) and insulin (23 mU/ml corresponding to 1.4 nM). When indicated, aSCF (100 ng/ml), retinoic acid (RA, 1 mM), and triiodothyronine (T3, 150 nM) were added. Cells were counted daily to follow proliferation kinetics and cell volume (Dolznig et al., 1995) and maintained at densities between 2 ± 4610 6 cells/ml by daily medium addition or partial medium changes plus re-addition of growth factors.
Analysis of dierentiation by cell morphology and staining
Cells were cytocentrifuged and subsequently stained with histological dyes and neutral benzidine for hemoglobin as described (Beug et al., 1982) . Images were taken using a CCD camera (Photometrics) and a blue ®lter (480 nm), so that mature, hemoglobin containing cells appear darkly stained. Images were processed using the Adobe Photoshop software.
Photometric hemoglobin assay 3650 ml aliquots of the cultures were removed and processed for photometric determination of hemoglobin as described (Kowenz et al., 1987) .
RNA extraction and analysis
Total RNA was prepared from between 1 to 4610 7 cells by lysis in guanidinium-iso-thiocyanate buer (GITC) and subsequent extraction with acid phenol as described earlier (Chomczynski and Sacchi, 1987) . The resulting preparations were subjected to an additional treatment with 200 mg/ml of Proteinase K for 30 min at 558C in a buer containing 0.5% SDS to remove the last traces of RNAses, extracted once more with phenol/chloroform and reprecipitated. For each sample, 10 mg of RNA was separated in 1% agarose gels containing formaldehyde, transferred to a nylon membrane (Gene Screen), ®xed by u.v. irradiation, methylene blue stained and hybridized sequentially with 32 P-labeled chicken speci®c probes for Band 3, carbonic anhydrase II, e-AlaS and c-myb (Briegel et al., 1993; Schroeder et al., 1993; Zenke et al., 1988 Zenke et al., , 1990 , generated by random-primed labeling. After washing, ®lters were exposed to X-ray ®lms at 7708C using intensifying screens.
Phosphotyrosine-and Western immunoblot analysis
For analysis of bioactive c-ErbB and c-Kit by phosphotyrosine blot, cells were washed twice in serum free DMEM and incubated in CFU-E medium minus growth factors overnight. Thereafter, TGFa (20 ng/ml), aSCF (1 mg/ml) or no factor was added to the cells for 10 min at 378C. The cells were then harvested by centrifugation, lysed and analysed by Western blot analysis using the monoclonal antibody 4G10 against phosphotyrosine from UBI (#05-321) as described (Crowe and Hayman, 1991) . V-ErbA expression was analysed using a rabbit antiserum to vErbA (Goldberg et al., 1988 ; a kind gift of J Ghysdael, Orsay, France). The enhanced chemiluminescence (ECL) detection system (Amersham) was used for visualisation of the proteins according to the instructions of the manufacturer.
